GlassScriptPhysician profile
Vikas Merchia
NPI 1811966948
$15,364.50
in general payments reported to CMS, 2019-2025
47 companies · $905 in 2025
The $905 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $2,042 · 2021: $2,163 · 2022: $3,368 · 2023: $4,214 · 2024: $1,212 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,903 · Travel and Lodging: $2,337 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.81 |
| Travel and Lodging | $2,336.92 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,487.07 | 2023 | |
| Axonics, INC. | $1,442.07 | 2020-2023 | Axonics |
| Boston Scientific Corporation | $1,384.58 | 2020-2025 | Advantage System, Solyx Sis System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,238.77 | 2019-2024 | Trulance, Xifaxan |
| Biotissue Holdings INC. | $1,203.39 | 2021-2024 | |
| Valencia Technologies Corporation | $1,119.11 | 2023 | Ecoin Device Kit |
| Dentsply Ih INC. | $813.15 | 2019-2022 | |
| Acessa Health INC. | $771.80 | 2021 | |
| Pfizer INC. | $688.85 | 2019-2024 | |
| Dentsply Ih Ab | $639.00 | 2022-2025 | Lofric, Lofric |
| Myovant Sciences INC. | $423.91 | 2021-2022 | |
| Abbvie INC. | $357.63 | 2019-2025 | |
| Therapeuticsmd, INC. | $321.69 | 2019-2022 | |
| Novo Nordisk INC | $276.71 | 2022-2024 | Wegovy |
| Sumitomo Pharma America, INC. | $259.06 | 2023-2025 | Myfembree, Gemtesa |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $247.77 | 2023-2025 | Ibsrela |
| Allergan, INC. | $246.65 | 2019-2021 | |
| Minerva Surgical, INC | $210.42 | 2019-2025 | |
| Exact Sciences Corporation | $198.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $170.03 | 2019-2024 | Veozah |
| Exeltis, USA INC. | $142.38 | 2021-2024 | Slynd, Solosec, Nuvessa |
| Daiichi Sankyo INC. | $120.09 | 2022-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $119.79 | 2019 | |
| Coopersurgical, INC. | $108.28 | 2024-2025 | Endosee, Paragard T 380a |
| Eisai INC. | $102.46 | 2023-2024 | |
| Hologic Sales and Service, LLC | $101.76 | 2020-2021 | |
| Medtronic, INC. | $90.53 | 2025 | Interstim, V-Loc 180 |
| Mayne Pharma Commercial LLC | $85.73 | 2021-2023 | |
| Vertex Pharmaceuticals Incorporated | $78.59 | 2024-2025 | |
| 180 Medical, INC. | $77.63 | 2019-2025 | Gentlecath Glide, Gentlecath |
| Agile Therapeutics, INC. | $74.46 | 2021-2022 | |
| Caldera Medical, INC | $72.95 | 2022 | |
| Acell, INC. | $72.64 | 2019 | |
| Shield Therapeutics INC | $68.90 | 2024-2025 | |
| Lupin INC. | $68.16 | 2019-2020 | |
| Evofem Biosciences, INC. | $65.48 | 2020-2021 | |
| Urovant Sciences INC | $61.83 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $60.21 | 2019 | |
| Millicent US INC | $56.51 | 2019 | |
| Aspira Women'S Health INC | $56.07 | 2021 | |
| Coloplast Corp | $53.15 | 2019 | |
| Azurity Pharmaceuticals, INC. | $35.59 | 2023 | Adthyza |
| Acella Pharmaceuticals, LLC | $33.27 | 2023-2025 | NP Thyroid 60 |
| Sage Therapeutics, LLC | $20.30 | 2024 | |
| Lilly USA, LLC | $13.83 | 2024 | Zepbound |
| Biohaven Pharmaceuticals, INC. | $12.31 | 2021 | |
| Organon LLC | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Merchia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.